Every round on record, with the sources behind each and the investors on them.
A clinical-stage medical technology company advancing Endoscopic Metabolic Restoration for the treatment of Type 2 diabetes
aquaendoscopy.comLinkedInHealthtech9 people
Published on thinner evidence: weigh the verdict and its sources before you rely on it.
The Relevance Ventures announcement is dated Sept. 23, while Aqua Medical’s release fixes the closing announcement to Sept. 24. The investor release says “multimillion”; Citybiz says the amount was not disclosed, so the reported amount remains qualified.
Published on thinner evidence: weigh the verdict and its sources before you rely on it.
The dateline identifies Santa Ana, Calif., but does not state that it is Aqua Medical's headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B Published on thinner evidence, 4 sources | n/a | 2026-09-24 | Relevance Ventures | 3 outlets. #84 in Trending |
[ VERIFIED ]0.85 Published on thinner evidence: weigh the verdict and its sources before you rely on it. read against 4 sources The Relevance Ventures announcement is dated Sept. 23, while Aqua Medical’s release fixes the closing announcement to Sept. 24. The investor release says “multimillion”; Citybiz says the amount was not disclosed, so the reported amount remains qualified. [ BUILT WITH ] | ||||
Aqua Medical is a clinical-stage medical technology company developing a minimally invasive, through-the-scope radiofrequency vapor ablation procedure (PIMA) to treat Type 2 diabetes.
| Round | Amount | Announced | Lead |
|---|---|---|---|
| Series A-3 | $8.2 million | 2020-09-01 | ShangBay Capital LLC |
Type 2 diabetes affects roughly 589 million people globally and drives more than $1 trillion in annual healthcare expenditures, while care has centered on pharmaceutical management and invasive surgery. Aqua is betting that a minimally invasive, no-fluoroscopy, through-the-endoscope PIMA procedure can improve metabolic outcomes; its 2026 Series B will fund completion of RESTORE-1 and preparation for a pivotal trial after 66 patients were treated outside the United States and four U.S. procedures, although the diabetes use remains investigational.
Checked against 10 sources today
Via Alexandria from FullEnrich: headcount, type, industry
Relevance Ventures[ LEAD ]| Series A Series A-3 Published on thinner evidence, 1 source[ HISTORY ]: An earlier round of this company, found through its checked dossier and read from its own announcement like any round. Not news: never sent, and left out of the feed unless you filter by date. | $8.2M | ~ 2020-09-01 | ShangBay Capital | No recent discussion |
[ VERIFIED ]0.68 Published on thinner evidence: weigh the verdict and its sources before you rely on it. read against 1 source The dateline identifies Santa Ana, Calif., but does not state that it is Aqua Medical's headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: history: Aqua Medical, Inc.·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]confirmedread back across 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]dossier built by the Firecrawl agent | ||||